Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 79Lung Neoplasms 32Adenocarcinoma of Lung 13Adenocarcinoma, Bronchiolo-Alveolar 9Breast Neoplasms 8Neoplasm Metastasis 7Pancreatic Neoplasms 6Neoplasms 6Melanoma 6Stomach Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Ovarian Neoplasms 5Esophageal Neoplasms 5Small Cell Lung Carcinoma 4Endometrial Neoplasms 4Colorectal Neoplasms 4Carcinoma, Ovarian Epithelial 4Urinary Bladder Neoplasms 3Pleural Effusion, Malignant 3Carcinoma, Renal Cell 3Thymoma 2Testicular Neoplasms 2Sarcoma 2Salivary Gland Neoplasms 2Prostatic Neoplasms 2Oropharyngeal Neoplasms 2Neoplasms, Unknown Primary 2Mouth Neoplasms 2Hypopharyngeal Neoplasms 2Head and Neck Neoplasms 2

Interventions

selpercatinib 3Trastuzumab 2Radiotherapy 2vandetanib 1trametinib 1tovorafenib 1tipifarnib 1sargramostim 1pralsetinib 1entrectinib 1dabrafenib 1cobimetinib 1alectinib 1aldesleukin 1Vemurafenib 1Taxes 1Tamoxifen 1Ritonavir 1Paclitaxel 1Nivolumab 1Interleukin-12 Subunit p35 1Interleukin-12 1Indinavir 1Gefitinib 1Famotidine 1Doxorubicin 1Docetaxel 1Cisplatin 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Cancer, Papillary × Taxes × Thoracic × Clear all
NCT04731467 2024-12-27

A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors

Purple Biotech Ltd.

Phase 1/2 Completed
79 enrolled
DermatologicEndocrineGastrointestinalGynecologicHead & NeckThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡